Vera Therapeutics, Inc. VERA
26.76 USD +0.01 (+0.04%)
As ofNov 20, 2026, 9:52 AM EST
26.29 Day range 26.96
25.58 52-week range 55.67
- YTD
- -47.16%
- 1 year
- -3.98%
News
benzinga.com Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $29 Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $34 to $29.
benzinga.com Guggenheim Maintains Buy on Vera Therapeutics, Lowers Price Target to $66 Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $76 to $66.
benzinga.com HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $75 HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $90 to $75.
benzinga.com Vera Therapeutics Q3 EPS $(1.30) Beats $(1.62) Estimate, Sales $10.277M Beat $3.398M Estimate Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.30) per share which beat the analyst consensus estimate of $(1.62) by 19.75 percent. This is a 3.17 percent decrease over losses of…
benzinga.com Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpoint Of Proteinuria Reduction At 36 Weeks Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that the final efficacy analysis for the ORIGIN 3 trial of TRUTAKNA in adults with primary IgA…
